{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"58"}]}],"title":"Any TEAE"},{"categories":[{"measurements":[{"groupId":"OG000","value":"53"}]}],"title":"TEAE related to study drug"},{"categories":[{"measurements":[{"groupId":"OG000","value":"36"}]}],"title":"TEAE with CTCAE severity grade >/=3"},{"categories":[{"measurements":[{"groupId":"OG000","value":"25"}]}],"title":"Serious adverse event"},{"categories":[{"measurements":[{"groupId":"OG000","value":"11"}]}],"title":"Serious adverse event related to study drug"},{"categories":[{"measurements":[{"groupId":"OG000","value":"16"}]}],"title":"Discontinued treatment due to adverse event"}],"denoms":[{"counts":[{"groupId":"OG000","value":"58"}],"units":"Participants"}],"description":"Counts of participants who had adverse events or treatment-emergent adverse events (TEAE, defined as newly occurring or worsening after first dose). Serious adverse events are reported from the time of informed consent. National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE version 3.0) were used to assess severity (1=mild, 2=moderate, 3=severe, 4=life threatening/disabling, 5=death). Relatedness to study drug was assessed by the investigator (Yes/No). Participants with multiple occurrences of an adverse event within a category are counted once within the category.","groups":[{"description":"Brentuximab vedotin 1.8 mg/kg every 3 weeks by IV infusion","id":"OG000","title":"Brentuximab Vedotin"}],"paramType":"NUMBER","populationDescription":"All participants who received treatment","reportingStatus":"POSTED","timeFrame":"up to 12 months","title":"Adverse Events by Severity, Seriousness, and Relationship to Treatment","type":"SECONDARY","unitOfMeasure":"participants"}